The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity
Authors:
- 18 February 2005
- journal article
- clinical trial
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 27 (4) , 176-184
Abstract
To define the lowest effective dose of botulinum toxin type A (Dysport) and safety in the treatment of adult patients with upper limb spasticity. This was a prospective, randomized, double-blind, dose-ranging study. Patients received either a placebo or one of three does of Dysport (350, 500 100) U) into five muscles of affected arm by anatomical and electromyography guidance. Efficacy was assessed periodically throughout the 6-month study period by the Modified Ashworth Scale (MAS), the Action Research Arm Test (ARA), the Barthel Index (BI) and the Visual Analogue Pain Scale (VAS). fifty patients were recruited. The four study groups were comparable at baseline with respect to their demographical characteristics and severity of spasticity. All doses of Dysport studied showed a significant reduction from baseline of muscle tone and pain compared to placebo. However, the effect of functional disability was best at a dose of 500 U and the peak improvement was at week 8 after injection. A dose of 1000 U Dysport produced such an excess degree of muscle weakening that the number of randomized patients was reduced to five. BI and ARA of all patients were decrease after injection. No other adverse event was considered related to the study medication. This study suggest that treatment with Dysport reduces muscle tone in adult patients with upper limb spasticity. The optimal dose for treatment of patients with residual voluntary movement in the upper limb appears to be 500 U.Keywords
This publication has 16 references indexed in Scilit:
- Effect of Intramuscular Botulinum Toxin Injection on Upper Limb Spasticity in Stroke PatientsAmerican Journal of Physical Medicine & Rehabilitation, 2002
- A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with strokeEuropean Journal of Neurology, 2001
- Pharmacology and immunology of botulinum toxin serotypesJournal of Neurology, 2001
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After StrokeStroke, 2000
- Managing Spasticity in Pediatric Cerebral Palsy Using a Very Low Dose of Botulinum Toxin Type AAmerican Journal of Physical Medicine & Rehabilitation, 2000
- Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patientsClinical Rehabilitation, 1997
- The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humansMovement Disorders, 1997
- Botulinum toxin type A in the treatment of upper extremity spasticityNeurology, 1996
- Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patientsNeuroscience Letters, 1995
- A performance test for assessment of upper limb function in physical rehabilitation treatment and researchInternational Journal of Rehabilitation Research, 1981